Efficacy of biological agents in the treatment of Erdheim-Chester disease

Br J Haematol. 2018 Nov;183(3):520-524. doi: 10.1111/bjh.14997. Epub 2017 Oct 30.

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.
³ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Pulmonary Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 29082516
DOI: 10.1111/bjh.14997

No abstract available

Keywords: Erdheim-Chester disease; etanercept; infliximab; interleukin 1 receptor antagonist protein; treatment outcome.

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Erdheim-Chester Disease / drug therapy*
Etanercept / administration & dosage*
Etanercept / adverse effects
Female
Humans
Infliximab / administration & dosage*
Infliximab / adverse effects
Interleukin 1 Receptor Antagonist Protein / administration & dosage*
Interleukin 1 Receptor Antagonist Protein / adverse effects
Male
Methotrexate / administration & dosage*
Methotrexate / adverse effects
Middle Aged
Prednisolone / administration & dosage*
Prednisolone / adverse effects
Retrospective Studies
Vemurafenib / administration & dosage*
Vemurafenib / adverse effects

Substances

Interleukin 1 Receptor Antagonist Protein
Vemurafenib
Prednisolone
Infliximab
Etanercept
Methotrexate